Neurodevelopmental findings in children 20-30 months of age with postnatal Zika infection at 1-12 months of age, Colombia, September-November 2017.
Zika virus
child development
eye
hearing
neurologic examination
Journal
Paediatric and perinatal epidemiology
ISSN: 1365-3016
Titre abrégé: Paediatr Perinat Epidemiol
Pays: England
ID NLM: 8709766
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
20
02
2020
revised:
10
04
2020
accepted:
01
05
2020
pubmed:
4
6
2020
medline:
25
11
2021
entrez:
4
6
2020
Statut:
ppublish
Résumé
Zika virus (ZIKV) infection during pregnancy can cause infant brain and eye abnormalities and has been associated with adverse neurodevelopmental outcomes in exposed infants. Evidence is limited on ZIKV's effects on children infected postnatally within the first year of life. To determine whether any adverse neurodevelopmental outcomes occurred in early childhood for children infected postnatally with ZIKV during infancy, given the neurotoxicity of ZIKV infection and the rapid brain development that occurs in infancy and early childhood. The Colombia Instituto Nacional de Salud (INS) conducted health and developmental screenings between September and November 2017 to evaluate 60 children at ages 20-30 months who had laboratory-confirmed symptomatic postnatal ZIKV infection at ages 1-12 months. We examined the frequency of adverse neurologic, hearing, eye, and developmental outcomes as well as the relationship between age at Zika symptom onset and developmental outcomes. Nine of the 60 (15.0%) children had adverse outcomes on the neurologic, hearing, or eye examination. Six of the 47 (12.8%) children without these adverse findings, and who received a valid developmental screening, had an alert score in the hearing-language domain which signals the need for additional developmental evaluation. Neurologic, hearing, eye, and developmental findings suggest reassuring results. Since the full spectrum of neurodevelopmental outcomes in children postnatally infected with ZIKV remains unknown, routine paediatric care is advised to monitor the development of these children to ensure early identification of any adverse neurodevelopmental outcomes.
Sections du résumé
BACKGROUND
Zika virus (ZIKV) infection during pregnancy can cause infant brain and eye abnormalities and has been associated with adverse neurodevelopmental outcomes in exposed infants. Evidence is limited on ZIKV's effects on children infected postnatally within the first year of life.
OBJECTIVE
To determine whether any adverse neurodevelopmental outcomes occurred in early childhood for children infected postnatally with ZIKV during infancy, given the neurotoxicity of ZIKV infection and the rapid brain development that occurs in infancy and early childhood.
METHODS
The Colombia Instituto Nacional de Salud (INS) conducted health and developmental screenings between September and November 2017 to evaluate 60 children at ages 20-30 months who had laboratory-confirmed symptomatic postnatal ZIKV infection at ages 1-12 months. We examined the frequency of adverse neurologic, hearing, eye, and developmental outcomes as well as the relationship between age at Zika symptom onset and developmental outcomes.
RESULTS
Nine of the 60 (15.0%) children had adverse outcomes on the neurologic, hearing, or eye examination. Six of the 47 (12.8%) children without these adverse findings, and who received a valid developmental screening, had an alert score in the hearing-language domain which signals the need for additional developmental evaluation.
CONCLUSION
Neurologic, hearing, eye, and developmental findings suggest reassuring results. Since the full spectrum of neurodevelopmental outcomes in children postnatally infected with ZIKV remains unknown, routine paediatric care is advised to monitor the development of these children to ensure early identification of any adverse neurodevelopmental outcomes.
Identifiants
pubmed: 32488915
doi: 10.1111/ppe.12690
pmc: PMC7708429
mid: NIHMS1634510
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-97Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Sci Transl Med. 2018 Apr 4;10(435):
pubmed: 29618564
N Engl J Med. 2020 Aug 6;383(6):e44
pubmed: 27305043
Dev Med Child Neurol. 2019 Oct;61(10):1139-1144
pubmed: 30680706
Lancet. 2016 Aug 27;388(10047):891-7
pubmed: 27372398
Paediatr Perinat Epidemiol. 2017 Nov;31(6):537-545
pubmed: 28806479
J Neurosci. 2008 Nov 19;28(47):12176-82
pubmed: 19020011
MMWR Recomm Rep. 2019 Jun 14;68(1):1-10
pubmed: 31194720
JAMA Pediatr. 2018 Jul 1;172(7):624-625
pubmed: 29813163
MMWR Morb Mortal Wkly Rep. 2018 Aug 10;67(31):858-867
pubmed: 30091967
J Pediatr. 2014 Oct;165(4):779-85
pubmed: 25063723
World Rev Nutr Diet. 2015;113:278-94
pubmed: 25906897